Recent Updates — FGEN

On September 30, 2026, Nasdaq notified Kyntra Bio that it failed to meet the continued listing requirements under Rule 5450(b), specifically lacking the required $50 million in total assets and total revenue for the most recent fiscal years. The company has timely requested a hearing before a Nasdaq Hearings Panel to seek an extension of up to 180 days to regain compliance, which stays any immediate delisting action pending the panel's decision. Kyntra Bio operates as a biotechnology company focused on developing therapeutic treatments.

Kyntra Bio reported second quarter 2026 financial results on August 13, 2026. The company recorded a net income of $12.0 million from continuing operations, or $2.96 per share, compared to a net loss of $13.7 million in the prior year period. This turnaround was primarily driven by a $30.9 million gain on the deconsolidation of a subsidiary. Total revenue for the quarter was negative $1.5 million, contrasting with positive $1.3 million in 2025. As of June 30, 2026, Kyntra Bio held $95.7 million in cash and investments. Clinically, enrollment continues in the Phase 2 trial for FG-3246 in metastatic castration-resistant prostate cancer, with an interim analysis expected in the fourth quarter of 2026. Additionally, the Phase 3 protocol for roxadustat in lower-risk myelodysplastic syndromes has been finalized, targeting initiation in late 2026. Kyntra Bio is a biopharmaceutical company focused on developing novel therapies in oncology and rare disease.